Burkhard Goke

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/11576526/burkhard-goke-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

 167
 10,668
 61
 97

 papers
 citations
 h-index
 g-index

 168
 11,416
 4.8
 5.58

 ext. papers
 ext. citations
 avg, IF
 L-index

#	Paper	IF	Citations
167	ECatenin acts as a tumor suppressor through context-dependent mechanisms in colorectal cancer. International Journal of Colorectal Disease, 2017, 32, 1243-1251	3	1
166	Cabozantinib and Tivantinib, but Not INC280, Induce Antiproliferative and Antimigratory Effects in Human Neuroendocrine Tumor Cells in vitro: Evidence for @ff-TargetŒffects Not Mediated by c-Met Inhibition. <i>Neuroendocrinology</i> , 2016 , 103, 383-401	5.6	18
165	A synthetic lethal screen identifies ATR-inhibition as a novel therapeutic approach for POLD1-deficient cancers. <i>Oncotarget</i> , 2016 , 7, 7080-95	3.3	32
164	Inactivation of BRCA2 in human cancer cells identifies a subset of tumors with enhanced sensitivity towards death receptor-mediated apoptosis. <i>Oncotarget</i> , 2016 , 7, 9477-90	3.3	3
163	Screening for Colorectal Cancer Is Associated With Lower Disease Stage: A Population-Based Study. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 1612-1618.e3	6.9	28
162	Mesenchymal stem cell-mediated, tumor stroma-targeted radioiodine therapy of metastatic colon cancer using the sodium iodide symporter as theranostic gene. <i>Journal of Nuclear Medicine</i> , 2015 , 56, 600-6	8.9	57
161	Effects of the glucagon-like peptide-1 receptor agonist liraglutide in juvenile transgenic pigs modeling a pre-diabetic condition. <i>Journal of Translational Medicine</i> , 2015 , 13, 73	8.5	22
160	Thyroid hormones and tetrac: new regulators of tumour stroma formation via integrin IIB. <i>Endocrine-Related Cancer</i> , 2015 , 22, 941-52	5.7	36
159	Establishment of an Effective Radioiodide Thyroid Ablation Protocol in Mice. <i>European Thyroid Journal</i> , 2015 , 4, 74-80	4.2	8
158	The NOD2 Single Nucleotide Polymorphism rs72796353 (IVS4+10 A>C) Is a Predictor for Perianal Fistulas in Patients with Crohn@ Disease in the Absence of Other NOD2 Mutations. <i>PLoS ONE</i> , 2015 , 10, e0116044	3.7	15
157	Additive Anti-Tumor Effects of Lovastatin and Everolimus In Vitro through Simultaneous Inhibition of Signaling Pathways. <i>PLoS ONE</i> , 2015 , 10, e0143830	3.7	11
156	Neuroendokrine Tumoren des Gastrointestinaltrakts 2015 , 569-578		
155	Rate and predictors of mucosal healing in patients with inflammatory bowel disease treated with anti-TNF-alpha antibodies. <i>PLoS ONE</i> , 2014 , 9, e99293	3.7	21
154	The NOD2 p.Leu1007fsX1008 mutation (rs2066847) is a stronger predictor of the clinical course of Crohn@ disease than the FOXO3A intron variant rs12212067. <i>PLoS ONE</i> , 2014 , 9, e108503	3.7	20
153	Anticancer effects of metformin on neuroendocrine tumor cells in vitro. <i>Hormones</i> , 2014 , 13, 498-508	3.1	18
152	DRO1 inactivation drives colorectal carcinogenesis in ApcMin/+ mice. <i>Molecular Cancer Research</i> , 2014 , 12, 1655-62	6.6	14
151	Oncostatin M mediates STAT3-dependent intestinal epithelial restitution via increased cell proliferation, decreased apoptosis and upregulation of SERPIN family members. <i>PLoS ONE</i> , 2014 , 9, e9	3 <i>4</i> 978	40

(2011-2014)

150	Aspirin inhibits cell viability and mTOR downstream signaling in gastroenteropancreatic and bronchopulmonary neuroendocrine tumor cells. <i>World Journal of Gastroenterology</i> , 2014 , 20, 10038-49	5.6	13
149	Stromal targeting of sodium iodide symporter using mesenchymal stem cells allows enhanced imaging and therapy of hepatocellular carcinoma. <i>Human Gene Therapy</i> , 2013 , 24, 306-16	4.8	39
148	The novel somatostatin receptor 2/dopamine type 2 receptor chimeric compound BIM-23A758 decreases the viability of human GOT1 midgut carcinoid cells. <i>Neuroendocrinology</i> , 2013 , 98, 128-36	5.6	15
147	Activation of cannabinoid receptor 2 reduces inflammation in acute experimental pancreatitis via intra-acinar activation of p38 and MK2-dependent mechanisms. <i>American Journal of Physiology - Renal Physiology</i> , 2013 , 304, G181-92	5.1	30
146	Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial. <i>International Journal of Clinical Practice</i> , 2013 , 67, 307-16	2.9	61
145	Systemic image-guided liver cancer radiovirotherapy using dendrimer-coated adenovirus encoding the sodium iodide symporter as theranostic gene. <i>Journal of Nuclear Medicine</i> , 2013 , 54, 1450-7	8.9	57
144	EGFR-Targeted Adenovirus Dendrimer Coating for Improved Systemic Delivery of the Theranostic NIS Gene. <i>Molecular Therapy - Nucleic Acids</i> , 2013 , 2, e131	10.7	47
143	Potent antitumor activity of the novel HSP90 inhibitors AUY922 and HSP990 in neuroendocrine carcinoid cells. <i>International Journal of Oncology</i> , 2013 , 43, 1824-32	4.4	28
142	IRGM variants and susceptibility to inflammatory bowel disease in the German population. <i>PLoS ONE</i> , 2013 , 8, e54338	3.7	51
141	Intestinal DMBT1 expression is modulated by Crohn@ disease-associated IL23R variants and by a DMBT1 variant which influences binding of the transcription factors CREB1 and ATF-2. <i>PLoS ONE</i> , 2013 , 8, e77773	3.7	18
140	Analysis of IL12B gene variants in inflammatory bowel disease. <i>PLoS ONE</i> , 2012 , 7, e34349	3.7	43
139	Changing metabolic signatures of amino acids and lipids during the prediabetic period in a pig model with impaired incretin function and reduced Etell mass. <i>Diabetes</i> , 2012 , 61, 2166-75	0.9	40
138	A novel role for interleukin-27 (IL-27) as mediator of intestinal epithelial barrier protection mediated via differential signal transducer and activator of transcription (STAT) protein signaling and induction of antibacterial and anti-inflammatory proteins. <i>Journal of Biological Chemistry</i> , 2012 ,	5.4	97
137	287, 286-298 The role of endogenous incretin secretion as amplifier of glucose-stimulated insulin secretion in healthy subjects and patients with type 2 diabetes. <i>Diabetes</i> , 2012 , 61, 2349-58	0.9	63
136	Perifosine-mediated Akt inhibition in neuroendocrine tumor cells: role of specific Akt isoforms. Endocrine-Related Cancer, 2012 , 19, 423-34	5.7	26
135	The role of 68Ga-DOTATATE PET/CT in suspected neuroendocrine tumors. <i>Journal of Nuclear Medicine</i> , 2012 , 53, 1686-92	8.9	114
134	PTPN2 gene variants are associated with susceptibility to both Crohn@ disease and ulcerative colitis supporting a common genetic disease background. <i>PLoS ONE</i> , 2012 , 7, e33682	3.7	46
133	Epidermal growth factor receptor-targeted (131)I-therapy of liver cancer following systemic delivery of the sodium iodide symporter gene. <i>Molecular Therapy</i> , 2011 , 19, 676-85	11.7	85

132	Therapeutic strategies for advanced neuroendocrine carcinomas of jejunum/ileum and pancreatic origin. <i>Gut</i> , 2011 , 60, 1009-21	19.2	63
131	Image-guided, tumor stroma-targeted 131I therapy of hepatocellular cancer after systemic mesenchymal stem cell-mediated NIS gene delivery. <i>Molecular Therapy</i> , 2011 , 19, 1704-13	11.7	66
130	Assessment of colon motility using simultaneous manometric and functional cine-MRI analysis: preliminary results. <i>Abdominal Imaging</i> , 2011 , 36, 24-30		26
129	Inhibition of ataxia telangiectasia- and Rad3-related function abrogates the in vitro and in vivo tumorigenicity of human colon cancer cells through depletion of the CD133(+) tumor-initiating cell fraction. Stem Cells, 2011, 29, 418-29	5.8	75
128	Pregnane X receptor (PXR/NR1I2) gene haplotypes modulate susceptibility to inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2011 , 17, 1917-24	4.5	30
127	Image-guided tumor-selective radioiodine therapy of liver cancer after systemic nonviral delivery of the sodium iodide symporter gene. <i>Human Gene Therapy</i> , 2011 , 22, 1563-74	4.8	39
126	Treatment with octreotide does not reduce tumor uptake of (68)Ga-DOTATATE as measured by PET/CT in patients with neuroendocrine tumors. <i>Journal of Nuclear Medicine</i> , 2011 , 52, 1679-83	8.9	53
125	The novel Raf inhibitor Raf265 decreases Bcl-2 levels and confers TRAIL-sensitivity to neuroendocrine tumour cells. <i>Endocrine-Related Cancer</i> , 2011 , 18, 277-85	5.7	21
124	CEACAM6 gene variants in inflammatory bowel disease. <i>PLoS ONE</i> , 2011 , 6, e19319	3.7	11
123	Risk of advanced colorectal neoplasia according to age and gender. <i>PLoS ONE</i> , 2011 , 6, e20076	3.7	58
122	Postnatal development of numbers and mean sizes of pancreatic islets and beta-cells in healthy mice and GIPR(dn) transgenic diabetic mice. <i>PLoS ONE</i> , 2011 , 6, e22814	3.7	27
121	The cannabinoid 1 receptor (CNR1) 1359 G/A polymorphism modulates susceptibility to ulcerative colitis and the phenotype in Crohn@ disease. <i>PLoS ONE</i> , 2010 , 5, e9453	3.7	40
120	Evidence for STAT4 as a common autoimmune gene: rs7574865 is associated with colonic Crohn@ disease and early disease onset. <i>PLoS ONE</i> , 2010 , 5, e10373	3.7	50
119	Expression of human chemerin induces insulin resistance in the skeletal muscle but does not affect weight, lipid levels, and atherosclerosis in LDL receptor knockout mice on high-fat diet. <i>Diabetes</i> , 2010 , 59, 2898-903	0.9	79
118	68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. <i>Journal of Nuclear Medicine</i> , 2010 , 51, 1349-56	8.9	162
117	Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis. <i>American Journal of Gastroenterology</i> , 2010 , 105, 1811-9	0.7	119
116	Glucose intolerance and reduced proliferation of pancreatic beta-cells in transgenic pigs with impaired glucose-dependent insulinotropic polypeptide function. <i>Diabetes</i> , 2010 , 59, 1228-38	0.9	141
115	Role of fat hydrolysis in regulating glucagon-like Peptide-1 secretion. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010 , 95, 879-86	5.6	109

(2008-2010)

114	Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease. <i>Cancer Letters</i> , 2010 , 295, 100-9	9.9	109
113	What are the potential benefits of clinical beta-cell imaging in diabetes mellitus?. <i>Current Pharmaceutical Design</i> , 2010 , 16, 1547-9	3.3	10
112	ECatenin is an independent prognostic marker in early stage colorectal cancer. <i>International Journal of Colorectal Disease</i> , 2010 , 25, 1301-9	3	9
111	The presence of fistulas and NOD2 homozygosity strongly predict intestinal stenosis in Crohn@ disease independent of the IL23R genotype. <i>Journal of Gastroenterology</i> , 2010 , 45, 721-31	6.9	39
110	Insulin glargine and NPH insulin increase to a similar degree epithelial cell proliferation and aberrant crypt foci formation in colons of diabetic mice. <i>Hormones and Cancer</i> , 2010 , 1, 320-30	5	18
109	Expression and regulation of the chemokine CXCL16 in Crohn@ disease and models of intestinal inflammation. <i>Inflammatory Bowel Diseases</i> , 2010 , 16, 1871-81	4.5	37
108	The NOD2 single nucleotide polymorphisms rs2066843 and rs2076756 are novel and common Crohn@ disease susceptibility gene variants. <i>PLoS ONE</i> , 2010 , 5, e14466	3.7	29
107	Comparative analysis of the lambda-interferons IL-28A and IL-29 regarding their transcriptome and their antiviral properties against hepatitis C virus. <i>PLoS ONE</i> , 2010 , 5, e15200	3.7	68
106	Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis. <i>European Journal of Endocrinology</i> , 2009 , 161, 339-44	6.5	224
105	Targeted radioiodine therapy of neuroblastoma tumors following systemic nonviral delivery of the sodium iodide symporter gene. <i>Clinical Cancer Research</i> , 2009 , 15, 6079-86	12.9	58
104	rs224136 on chromosome 10q21.1 and variants in PHOX2B, NCF4, and FAM92B are not major genetic risk factors for susceptibility to Crohn@ disease in the German population. <i>American Journal of Gastroenterology</i> , 2009 , 104, 665-72	0.7	20
103	Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009 , 36, 765-70	8.8	173
102	ITF-2 is disrupted via allelic loss of chromosome 18q21, and ITF-2B expression is lost at the adenoma-carcinoma transition. <i>Gastroenterology</i> , 2009 , 137, 639-48, 648.e1-9	13.3	25
101	Novel genetic risk markers for ulcerative colitis in the IL2/IL21 region are in epistasis with IL23R and suggest a common genetic background for ulcerative colitis and celiac disease. <i>American Journal of Gastroenterology</i> , 2009 , 104, 1737-44	0.7	67
100	Epistasis between Toll-like receptor-9 polymorphisms and variants in NOD2 and IL23R modulates susceptibility to Crohn@disease. <i>American Journal of Gastroenterology</i> , 2009 , 104, 1723-33	0.7	56
99	rs224136 on Chromosome 10q21.1 and Variants in PHOX2B, NCF4, and FAM92B Are Not Major Genetic Risk Factors for Susceptibility to Crohn Disease in the German Population. <i>American Journal of Gastroenterology</i> , 2009 , 104, 665-672	0.7	1
98	Genotype-phenotype analysis of the CXCL16 p.Ala181Val polymorphism in inflammatory bowel disease. <i>Clinical Immunology</i> , 2008 , 127, 49-55	9	16
97	The role of interleukin-22 in hepatitis C virus infection. <i>Cytokine</i> , 2008 , 41, 209-16	4	74

96	PI(3)K-Akt-mTOR pathway as a potential therapeutic target in neuroendocrine tumors. <i>Expert Review of Endocrinology and Metabolism</i> , 2008 , 3, 207-222	4.1	2
95	The ATG16L1 gene variants rs2241879 and rs2241880 (T300A) are strongly associated with susceptibility to Crohn@ disease in the German population. <i>American Journal of Gastroenterology</i> , 2008 , 103, 682-91	0.7	87
94	Type 2 diabetes mellitus as risk factor for colorectal cancer. <i>Archives of Physiology and Biochemistry</i> , 2008 , 114, 84-98	2.2	86
93	Functional sodium iodide symporter expression in breast cancer xenografts in vivo after systemic treatment with retinoic acid and dexamethasone. <i>Breast Cancer Research and Treatment</i> , 2008 , 109, 26	53- 172	27
92	The potential of 211Astatine for NIS-mediated radionuclide therapy in prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008 , 35, 1272-81	8.8	40
91	Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB1 and CB2 receptors. <i>Journal of Molecular Medicine</i> , 2008 , 86, 925-36	5.5	132
90	Linking genetic susceptibility to Crohn@disease with Th17 cell function: IL-22 serum levels are increased in Crohn@disease and correlate with disease activity and IL23R genotype status. <i>Inflammatory Bowel Diseases</i> , 2008 , 14, 204-12	4.5	146
89	Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): upregulated colonic IL-17F expression in active Crohn@ disease and analysis of the IL17F p.His161Arg polymorphism in IBD. <i>Inflammatory Bowel Diseases</i> , 2008 , 14, 437-45	4.5	254
88	Correlation of magnetic resonance enteroclysis (MRE) and wireless capsule endoscopy (CE) in the diagnosis of small bowel lesions in Crohn@ disease. <i>Inflammatory Bowel Diseases</i> , 2008 , 14, 1219-28	4.5	97
87	rs1004819 is the main disease-associated IL23R variant in German Crohn@ disease patients: combined analysis of IL23R, CARD15, and OCTN1/2 variants. <i>PLoS ONE</i> , 2007 , 2, e819	3.7	112
86	Macrophage migration inhibitory factor (MIF) -173G/C promoter polymorphism influences upper gastrointestinal tract involvement and disease activity in patients with Crohn@ disease. <i>Inflammatory Bowel Diseases</i> , 2007 , 13, 71-82	4.5	38
85	Medical treatment of gastrinomas. Wiener Klinische Wochenschrift, 2007, 119, 609-15	2.3	10
84	IL-22-mediated liver cell regeneration is abrogated by SOCS-1/3 overexpression in vitro. <i>American Journal of Physiology - Renal Physiology</i> , 2007 , 292, G1019-28	5.1	87
83	The effects of tesaglitazar as add-on treatment to metformin in patients with poorly controlled type 2 diabetes. <i>Diabetes and Vascular Disease Research</i> , 2007 , 4, 204-13	3.3	18
82	Application of 188rhenium as an alternative radionuclide for treatment of prostate cancer after tumor-specific sodium iodide symporter gene expression. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 4451-8	5.6	48
81	The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. <i>Neuroendocrinology</i> , 2007 , 85, 54-60	5.6	139
80	Interleukin 31 mediates MAP kinase and STAT1/3 activation in intestinal epithelial cells and its expression is upregulated in inflammatory bowel disease. <i>Gut</i> , 2007 , 56, 1257-65	19.2	82
79	SOCS1 silencing enhances antitumor activity of type I IFNs by regulating apoptosis in neuroendocrine tumor cells. <i>Cancer Research</i> , 2007 , 67, 5025-32	10.1	45

78	Eight novel CARD15 variants detected by DNA sequence analysis of the CARD15 gene in 111 patients with inflammatory bowel disease. <i>Immunogenetics</i> , 2006 , 58, 99-106	3.2	42
77	Cell differentiation dependent expressed CCR6 mediates ERK-1/2, SAPK/JNK, and Akt signaling resulting in proliferation and migration of colorectal cancer cells. <i>Journal of Cellular Biochemistry</i> , 2006 , 97, 709-23	4.7	120
76	IL-22 is increased in active Crohn@ disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. <i>American Journal of Physiology - Renal Physiology</i> , 2006 , 290, G827-38	3 ^{5.1}	437
75	Methylation of serum DNA is an independent prognostic marker in colorectal cancer. <i>Clinical Cancer Research</i> , 2006 , 12, 7347-52	12.9	154
74	Increased expression of the chemokine fractalkine in CrohnQ disease and association of the fractalkine receptor T280M polymorphism with a fibrostenosing disease Phenotype. <i>American Journal of Gastroenterology</i> , 2006 , 101, 99-106	0.7	84
73	Homozygosity for the CARD15 frameshift mutation 1007fs is predictive of early onset of Crohn@ disease with ileal stenosis, entero-enteral fistulas, and frequent need for surgical intervention with high risk of re-stenosis. <i>Scandinavian Journal of Gastroenterology</i> , 2006 , 41, 1421-32	2.4	64
72	Novel interferon-lambdas induce antiproliferative effects in neuroendocrine tumor cells. Biochemical and Biophysical Research Communications, 2006 , 344, 1334-41	3.4	99
71	A new technique for in vivo imaging of specific GLP-1 binding sites: first results in small rodents. <i>Regulatory Peptides</i> , 2006 , 137, 162-7		72
70	Nodular regenerative hyperplasia: a reversible entity associated with azathioprine therapy. <i>European Journal of Gastroenterology and Hepatology</i> , 2006 , 18, 553-5	2.2	41
69	Predictive value of the CARD15 variant 1007fs for the diagnosis of intestinal stenoses and the need for surgery in Crohn@ disease in clinical practice: results of a prospective study. <i>Inflammatory Bowel Diseases</i> , 2006 , 12, 1114-21	4.5	75
68	Gastrointestinale Hormonsysteme und ihre Regulation 2006 , 261-290		
67	CXCR4 and CXCL12 are inversely expressed in colorectal cancer cells and modulate cancer cell migration, invasion and MMP-9 activation. <i>Experimental Cell Research</i> , 2005 , 310, 117-30	4.2	136
66	Analysis of promoter methylation in stool: a novel method for the detection of colorectal cancer. <i>Clinical Gastroenterology and Hepatology</i> , 2005 , 3, 142-9	6.9	98
65	A multicenter assessment of liver toxicity by MRI and biopsy in IBD patients on 6-thioguanine. Journal of Hepatology, 2005 , 43, 303-9	13.4	78
64	SOCS-1 inhibits expression of the antiviral proteins 2Q5QOAS and MxA induced by the novel interferon-lambdas IL-28A and IL-29. <i>Biochemical and Biophysical Research Communications</i> , 2005 , 331, 543-8	3.4	77
63	The physiological role of GLP-1 in human: incretin, ileal brake or more?. <i>Regulatory Peptides</i> , 2005 , 128, 109-15		98
62	The role of Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms and CARD15/NOD2 mutations in the susceptibility and phenotype of Crohn@disease. <i>Inflammatory Bowel Diseases</i> , 2005 , 11, 645-52	4.5	127
61	IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression. <i>American Journal of Physiology - Renal Physiology</i> , 2005 , 289, G960-8	5.1	163

60	DRO1, a gene down-regulated by oncogenes, mediates growth inhibition in colon and pancreatic cancer cells. <i>Journal of Biological Chemistry</i> , 2005 , 280, 7962-75	5.4	42
59	A novel therapeutic strategy for medullary thyroid cancer based on radioiodine therapy following tissue-specific sodium iodide symporter gene expression. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 4457-64	5.6	56
58	Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study. <i>European Journal of Gastroenterology and Hepatology</i> , 2004 , 16, 1167-71	2.2	102
57	International Union of Pharmacology. XXXV. The glucagon receptor family. <i>Pharmacological Reviews</i> , 2003 , 55, 167-94	22.5	402
56	Use of the incretin hormone glucagon-like peptide-1 (GLP-1) for the detection of insulinomas: initial experimental results. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2002 , 29, 597-606	8.8	86
55	Combining infliximab with 6-mercaptopurine/azathioprine for fistula therapy in Crohn@ disease. <i>American Journal of Gastroenterology</i> , 2002 , 97, 2022-5	0.7	63
54	Novel insulin sensitizers: pharmacogenomic aspects. <i>Pharmacogenomics</i> , 2002 , 3, 99-116	2.6	31
53	Wnt/beta-catenin/tcf signaling: a critical pathway in gastrointestinal tumorigenesis. <i>Digestion</i> , 2002 , 66, 131-44	3.6	242
52	Improved glycemic control and lipid profile in a randomized study of pioglitazone compared with acarbose in patients with type 2 diabetes mellitus. <i>Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders</i> , 2002 , 1, 329-36		38
51	COLONIC DYSPLASIAS IN IBD PATIENTS ARE LESS FREQUENT THAN EXPECTED. Journal of Gastroenterology and Hepatology (Australia), 2001 , 16, 23-23	4	
50		3.6	55
	Gastroenterology and Hepatology (Australia), 2001, 16, 23-23 Pioglitazone inhibits growth of carcinoid cells and promotes TRAIL-induced apoptosis by induction		55 28
50	Gastroenterology and Hepatology (Australia), 2001, 16, 23-23 Pioglitazone inhibits growth of carcinoid cells and promotes TRAIL-induced apoptosis by induction of p21waf1/cip1. Digestion, 2001, 64, 75-80 GLP-1-induced alterations in the glucose-stimulated insulin secretory dose-response curve.	3.6	
50 49	Pioglitazone inhibits growth of carcinoid cells and promotes TRAIL-induced apoptosis by induction of p21waf1/cip1. Digestion, 2001, 64, 75-80 GLP-1-induced alterations in the glucose-stimulated insulin secretory dose-response curve. American Journal of Physiology - Endocrinology and Metabolism, 2001, 281, E242-7 Integrative mitogenic role of protein kinase B/Akt in beta-cells. Annals of the New York Academy of	3.6	28
50 49 48	Pioglitazone inhibits growth of carcinoid cells and promotes TRAIL-induced apoptosis by induction of p21waf1/cip1. Digestion, 2001, 64, 75-80 GLP-1-induced alterations in the glucose-stimulated insulin secretory dose-response curve. American Journal of Physiology - Endocrinology and Metabolism, 2001, 281, E242-7 Integrative mitogenic role of protein kinase B/Akt in beta-cells. Annals of the New York Academy of Sciences, 2000, 921, 242-50	3.6 6 6.5	28 47
50 49 48 47	Pioglitazone inhibits growth of carcinoid cells and promotes TRAIL-induced apoptosis by induction of p21waf1/cip1. <i>Digestion</i> , 2001 , 64, 75-80 GLP-1-induced alterations in the glucose-stimulated insulin secretory dose-response curve. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2001 , 281, E242-7 Integrative mitogenic role of protein kinase B/Akt in beta-cells. <i>Annals of the New York Academy of Sciences</i> , 2000 , 921, 242-50 Regulation of TRAIL-induced apoptosis by transcription factors. <i>Cellular Immunology</i> , 2000 , 201, 77-82 Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> ,	3.6 6 6.5	28 47 58
50 49 48 47 46	Pioglitazone inhibits growth of carcinoid cells and promotes TRAIL-induced apoptosis by induction of p21waf1/cip1. <i>Digestion</i> , 2001 , 64, 75-80 GLP-1-induced alterations in the glucose-stimulated insulin secretory dose-response curve. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2001 , 281, E242-7 Integrative mitogenic role of protein kinase B/Akt in beta-cells. <i>Annals of the New York Academy of Sciences</i> , 2000 , 921, 242-50 Regulation of TRAIL-induced apoptosis by transcription factors. <i>Cellular Immunology</i> , 2000 , 201, 77-82 Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 1999 , 276, R1541-4 Gene expression of the human glucagon-like peptide-1 receptor is regulated by Sp1 and Sp3.	3.6 6 6.5 4.4 3.2	28 47 58 169

42	Membrane dipeptidase and glutathione are major components of pig pancreatic zymogen granules. Experimental Cell Research, 1998 , 244, 481-90	4.2	7
41	The positive charge of the imidazole side chain of histidine7 is crucial for GLP-1 action. <i>Endocrine Journal</i> , 1997 , 44, 701-5	2.9	27
40	Incretin hormone expression in the gut of diabetic mice and rats. <i>Metabolism: Clinical and Experimental</i> , 1997 , 46, 261-7	12.7	30
39	Five out of six tryptophan residues in the N-terminal extracellular domain of the rat GLP-1 receptor are essential for its ability to bind GLP-1. <i>Peptides</i> , 1997 , 18, 301-5	3.8	42
38	Cloning and characterization of the 5 <i>Q</i> lanking sequences (promoter region) of the human GLP-1 receptor gene. <i>Peptides</i> , 1997 , 18, 617-24	3.8	22
37	Endoproteolysis of glucagon-like peptide (GLP)-1 (7-36) amide by ectopeptidases in RINm5F cells. <i>Peptides</i> , 1997 , 18, 625-32	3.8	65
36	Leptin: a potent inhibitor of insulin secretion. <i>Peptides</i> , 1997 , 18, 1267-73	3.8	79
35	Exchange of W39 by A within the N-terminal extracellular domain of the GLP-1 receptor results in a loss of receptor function. <i>Peptides</i> , 1996 , 17, 565-70	3.8	24
34	Galanin is a potent inhibitor of glucagon-like peptide-1 secretion from rat ileum. <i>Peptides</i> , 1996 , 17, 571	1 -6 .8	26
33	The isolated N-terminal extracellular domain of the glucagon-like peptide-1 (GLP)-1 receptor has intrinsic binding activity. <i>FEBS Letters</i> , 1996 , 398, 43-7	3.8	43
32	Studies on the viability of the isolated vascularly perfused rat colon. <i>Digestion</i> , 1996 , 57, 349-55	3.6	9
31	Ligand-induced regulation of glucagon-like peptide-I receptor function and expression in insulin-secreting beta cells. <i>Pancreas</i> , 1996 , 13, 273-82	2.6	14
30	Regulation of glucagon-like peptide-I receptor expression and transcription by the protein kinase C pathway. <i>Research in Experimental Medicine</i> , 1996 , 196, 219-25		2
29	Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. <i>Digestion</i> , 1995 , 56, 117-26	3.6	442
28	Regulation of islet hormone gene expression by incretin hormones. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 1995 , 103 Suppl 2, 56-65	2.3	12
27	Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide. <i>Endocrine Reviews</i> , 1995 , 16, 390-410	27.2	444
26	Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. <i>Regulatory Peptides</i> , 1995 , 58, 149-56		172
25	Characterization of GIP(1-30) and GIP(1-42) as stimulators of proinsulin gene transcription. <i>Peptides</i> , 1995 , 16, 1149-52	3.8	39

24	Molecular cloning, functional expression, and signal transduction of the GIP-receptor cloned from a human insulinoma. <i>FEBS Letters</i> , 1995 , 373, 23-9	3.8	65
23	The effects of glucagon-like peptide-I (GLP-I) on hormone secretion from isolated human pancreatic islets. <i>Pancreas</i> , 1995 , 11, 196-200	2.6	51
22	Glycosylation of the GLP-1 receptor is a prerequisite for regular receptor function. <i>Peptides</i> , 1994 , 15, 675-81	3.8	26
21	Stable expression of the rat GLP-I receptor in CHO cells: activation and binding characteristics utilizing GLP-I(7-36)-amide, oxyntomodulin, exendin-4, and exendin(9-39). <i>Peptides</i> , 1994 , 15, 453-6	3.8	68
20	Signal transduction of the GLP-1-receptor cloned from a human insulinoma. <i>FEBS Letters</i> , 1994 , 348, 7-13	3.8	37
19	Ras antagonizes cAMP stimulated glucagon gene transcription in pancreatic islet cell lines. <i>FEBS Letters</i> , 1994 , 353, 277-80	3.8	3
18	Protein kinase C activates capacitative calcium entry in the insulin secreting cell line RINm5F. <i>FEBS Letters</i> , 1994 , 339, 307-11	3.8	49
17	Interaction of glucagon-like peptide-I (7-37) and somatostatin-14 on signal transduction and proinsulin gene expression in beta TC-1 cells. <i>Metabolism: Clinical and Experimental</i> , 1994 , 43, 787-92	12.7	14
16	Detection of the human glucagon-like peptide 1(7-36) amide receptor on insulinoma-derived cell membranes. <i>Digestion</i> , 1994 , 55, 29-33	3.6	38
15	Glucose-dependency of the insulin stimulatory effect of glucagon-like peptide-1 (7-36) amide on the rat pancreas. <i>Research in Experimental Medicine</i> , 1993 , 193, 97-103		73
14	Glucagon-like peptide-1(7-37)/(7-36)amide is a new incretin. <i>Molecular and Cellular Endocrinology</i> , 1992 , 85, C39-44	4.4	67
13	Solubilization of active GLP-1 (7-36)amide receptors from RINm5F plasma membranes. <i>FEBS Letters</i> , 1992 , 300, 232-6	3.8	25
12	Expression of the ras-related rab3a gene in insulinoma-derived cell lines. FEBS Letters, 1992, 312, 183-6	3.8	8
11	Characterization of glucagon-like peptide-I(7-36)amide receptors of rat lung membranes by covalent cross-linking. <i>FEBS Letters</i> , 1991 , 280, 247-50	3.8	29
10	Priming effect of glucagon-like peptide-1 (7-36) amide, glucose-dependent insulinotropic polypeptide and cholecystokinin-8 at the isolated perfused rat pancreas. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1991 , 1091, 356-63	4.9	25
9	Atrial natriuretic peptide levels reflect hemodynamic changes under pacemaker stimulation. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1990 , 13, 970-5	1.6	8
8	A critical appraisal of studies of the pancreas. <i>International Journal of Gastrointestinal Cancer</i> , 1990 , 6, 181-188		1
7	Characterization of receptors for glucagon-like peptide-1(7-36)amide on rat lung membranes. <i>FEBS Letters</i> , 1990 , 267, 78-80	3.8	29

LIST OF PUBLICATIONS

6	Interaction of glucagon-like peptide-1(7-36)amide and somatostatin-14 in RINm5F cells and in the perfused rat pancreas. <i>Pancreas</i> , 1989 , 4, 668-73	2.6	29
5	Differential effects of atropine and a cholecystokinin receptor antagonist on pancreatic secretion. <i>Gastroenterology</i> , 1989 , 96, 1158-64	13.3	79
4	RECEPTORS FOR ATRIAL NATRIURETIC PEPTIDE ON ISOLATED RAT ADIPOCYTES . <i>Biomedical Research</i> , 1989 , 10, 463-467	1.5	15
3	Influence of a small molecular weight proteinase inhibitor, gabexate mesilate (FOY), on insulin receptor function in vitro. <i>International Journal of Gastrointestinal Cancer</i> , 1988 , 3, 135-42		
2	Endogenous CCK release and pancreatic growth in rats after feeding a proteinase inhibitor (camostate). <i>Pancreas</i> , 1986 , 1, 509-15	2.6	113
1	[Effect of a specific serine protease inhibitor on the rat pancreas. II. Influence of camostate on the endocrine pancreas]. <i>Digestion</i> , 1985 , 31, 128-35	3.6	12